

California Institute of Technology
Supporting Caltech’s pioneering oncotripsy research to offer gentler, targeted cancer treatments.
Why Oncotripsy
Our Mission
We aim to accelerate clinical trials, making oncotripsy accessible as a safer alternative to chemo and radiation.
Oncotripsy Research
@ Caltech
Innovative cancer treatment protocol at Caltech.
Why Oncotripsy
Because it targets cancer cells precisely, sparing healthy tissue.
Mechanism of Action: Research indicates that oncotripsy, particularly using Low-Intensity Pulsed Ultrasound (LIPUS), breaks down the cytoskeleton of cancer cells by identifying specific, target-cell-matched frequencies.
Mathematical Modeling: Professors such as Michael Ortiz have developed, and continue to refine, mathematical models to predict how cell structures react to different acoustic waves.
Computational/Experimental Validation: Studies show that specific pulse durations (e.g., 30 ms) disrupt the actin ring in cancer cells. Research, in collaboration with the City of Hope Beckman Research Institute, has shown potential for targeting solid tumors, such as hepatocellular carcinoma (HCC), without affecting healthy tissues.
Viscoelastic Modeling: Subsequent studies investigated the influence of viscoelasticity and damping on the oncotripsy effect, establishing it as a form of mechanical cell fatigue.
This work is primarily driven by the Gharib Research Group and collaborators to advance it as a non-invasive treatment option.
The information regarding oncotripsy is based on current research and clinical trials. Its full benefits, limitations, and side effect profile in broad clinical use are still being determined.
Support Trials
Your donations accelerate clinical research progress.
